RecruitingNCT05970237
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment
9,000 participants
Start Date
Jul 26, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
- Those who voluntarily signed a written personal information agreement to participate in this clinical study.
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion Criteria4
- Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
- Those who are expected to need insulin prescription during the study period
- Pregnant women, breast-feeding women
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05970237
Related Trials
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT052937561 location
Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension
NCT074614154 locations
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT074820201 location